Isocorydine inhibits the proliferation of human endometrial carcinoma HEC-1B cells by downregulating the Ras/MEK/ERK signaling pathway

Objective: Isocorydine (ICD), an aporphine alkaloid, plays a role in anticancer activity that is still being evaluated. However, the exact function and mechanism of ICD in endometrial carcinoma is largely unknown. Methods: MTT, flow cytometry, western blot, immunofluorescence, RT-PCR and ELISA were used in this research. Results: In our study we showed that ICD inhibited endometrial carcinoma HEC-1B cell proliferation at certain times and concentrations. Simultaneously, ICD induced HEC-1B cells apoptosis. Further investigation indicated that ICD reduced the phosphorylation protein levels of c-Raf (rapidly accelerated fibrosarcoma), MEK1/2 (MAPK/Erk kinase) and ERK1/2 (extracellular regulated protein kinase). Moreover, a cell immunofluorescence assay confirmed that ICD reduced intracellular expression of Ras and then promoted FOXO3 (forkhead box O3) nuclear localization to furtherly increase the mRNA level of Bim and p27Kip1. Additionally, an enzyme-linked immunosorbent assay (ELISA) revealed that ICD inhibited the production of EGF (epidermal growth factor) and PDGF (Platelet-Derived Growth Factor), which indicated that ICD indirectly inhibited the activation of the Ras/MEK/ERK signaling pathway at the ligand level. Conclusion: Taken together, these data suggest for the first time that ICD inhibits cell proliferation and induces cell apoptosis in endometrial carcinoma through suppressing Ras/MEK/ERK signaling, which may provide a theoretical foundation to the application of ICD for the treatment of human endometrial carcinoma.

Isocorydione; Endometrial carcinoma; Proliferation; Ras/MEK/ERK signaling pathway

[1] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians. 2015; 65: 87–108.

[2] Lucic N, Draganovic D, Sibincic S, EcimZlojutro V, Milicevic S. Myometrium invasion, tumour size and lymphovascular invasion as a prognostic factor in dissemination of pelvic lymphatics at endometrial carcinoma. Medical Archives. 2017; 71: 325.

[3] Busch EL, Crous-Bou M, Prescott J, Downing MJ, Rosner BA, Mutter GL, et al. Adiponectin, leptin, and insulin-pathway receptors as endometrial cancer subtyping markers. Hormones and Cancer. 2018; 9: 33–39.

[4] Wang Y, Dai C, Zhou C, Li W, Qian Y, Wen J, et al. Benzotriazole enhances cell invasive potency in endometrial carcinoma through ctbp1-mediated epithelial-mesenchymal transition. Cellular Physiology and Biochemistry. 2017; 44: 2357–2367.

[5] Chaudhary S, Ponnala S, Legendre O, Gonzales JA, Navarro HA, Harding WW. New aporphinoid 5-HT2A and alpha1A antagonists via structural manipulations of nantenine. Bioorganic & Medicinal Chemistry. 2011; 19: 5861–5868.

[6] Lu P, Sun H, Zhang L, Hou H, Zhang L, Zhao F, et al. Isocorydine targets the drug-resistant cellular side population through pdcd4-related apoptosis in hepatocellular carcinoma. Molecular Medicine. 2012; 18: 1136–1146.

[7] Sun H, Hou H, Lu P, Zhang L, Zhao F, Ge C, et al. Isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/M cell cycle arrest and apoptosis. PLoS One. 2012; 7: e36808.

[8] Yan Q, Li R, Xin A, Han Y, Zhang Y, Liu J, et al. Design, synthesis, and anticancer properties of isocorydine derivatives. Bioorganic & Medicinal Chemistry. 2017; 25: 6542–6553.

[9] Li M, Zhang L, Ge C, Chen L, Fang T, Li H, et al. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma. Oncotarget. 2015; 6: 25149–25160.

[10] Jokinen E, Laurila N, Koivunen JP. Alternative dosing of dual PI3K and MEK inhibition in cancer therapy. BMC Cancer. 2012; 12: 612.

[11] Kamal A, Faazil S, Ramaiah MJ, Ashraf M, Balakrishna M, Pushpavalli SNCVL, et al. Synthesis and study of benzothiazole conjugates in the control of cell proliferation by modulating Ras/MEK/ERK-dependent pathway in MCF-7 cells. Bioorganic & Medicinal Chemistry Letters. 2013; 23: 5733–5739.

[12] Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007; 26: 3291–3310.

[13] Wang S, Liang Q, Qiao H, Li H, Shen T, Ji F, et al. DISC1 regulates astrogenesis in the embryonic brain via modulation of RAS/MEK/ERK signaling through RASSF7. Development. 2017; 143: 2732–2740.

[14] Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene. 2005; 24: 7410–7425.

[15] Paik J, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, et al. FoxOs are Lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell. 2007; 128: 309–323.

[16] Yang J, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nature Cell Biology. 2008; 10: 138–148.

[17] Tran H, Brunet A, Griffith EC, Greenberg ME. The many Forks in FOXO’s Road. Science Signaling. 2003; 2003: re5.

[18] Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NSB, Lam EW, et al. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27KIP1. Molecular and Cellular Biology. 2000; 20: 9138–9148.

[19] McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EWT, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica Et Biophysica Acta (BBA)- Molecular Cell Research. 2007; 1773: 1263–1284.

[20] Wright CW, Marshall SJ, Russell PF, Anderson MM, Phillipson JD, Kirby GC, et al. In vitro antiplasmodial, antiamoebic, and cytotoxic activities of some monomeric isoquinoline alkaloids. Journal of Natural Products. 2000; 63: 1638–1640.

[21] Qin C, Fan W, Liu Q, Shang K, Murugan M, Wu L, et al. Fingolimod protects against ischemic white matter damage by modulating microglia toward M2 polarization via STAT3 pathway. Stroke. 2017; 48: 3336-3346.

[22] Wu R, Li H, Li T, Zhang Y, Zhu D. Myostatin regulates miR-431 expression via the Ras-Mek-Erk signaling pathway. Biochemical and Biophysical Research Communications. 2015; 461: 224–229.

[23] Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G, et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene. 2003; 22: 6785–6793.

[24] Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002; 418: 934.

[25] Butler DE, Marlein C, Walker HF, Frame FM, Mann VM, Simms MS, et al. Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer. Oncotarget. 2017; 8: 56698–56713.

[26] Zhang P, Kawakami H, Liu W, Zeng X, Strebhardt K, Tao K, et al. Targeting CDK1 and MEK/ERK overcomes apoptotic resistance in BRAF-mutant human colorectal cancer. Molecular Cancer Research. 2018; 16: 378–389.

[27] Yu C, Zhang Z, Liao W, Zhao X, Liu L, Wu Y, et al. The tumor-suppressor gene Nkx2.8 suppresses bladder cancer proliferation through upregulation of FOXO3a and inhibition of the MEK/ERK signaling pathway. Carcinogenesis. 2012; 33: 678– 686.

[28] Liu Y, Yi L, Wang L, Chen L, Chen X, Wang Y. Ginsenoside Rg1 protects human umbilical cord blood-derived stromal cells against tert-Butyl hydroperoxide-induced apoptosis through Akt- FoxO3a-Bim signaling pathway. Molecular and Cellular Biochemistry. 2016; 421: 75–87.